Jefferies Maintains a 'Buy' on Immunogen Inc. (IMGN); EMILIA Becomes Statistically Significant

Jefferies maintains a 'Buy' on Immunogen Inc. (NASDAQ: IMGN) price target of $19.00.

Analyst, Thomas Wei, said, "Roche (OTC: RHHBY) and IMGN provided updated overall survival results from the second-line metastatic breast EMILIA Phase 3 trial, which shows a statistically significant benefit for T-DM1 over standard Tykerb+Xeloda. We believe this is incrementally positive for T-DM1, although we have expected a significant survival benefit given the positive interim trend. We continue to believe T-DM1 will become the preferred backbone in HER2 breast cancer."

For an analyst ratings summary and ratings history on Immunogen Inc. click here. For more ratings news on Immunogen Inc. click here.

Shares of Immunogen Inc. closed at $14.62 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• KinderCare Learning Companies (KLC) PT Lowered to $4.50 at UBS
• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating